KALARIS THERAPEUTICS INC (KLRS) Stock News

USA - NASDAQ:KLRS - US4829291065 - Common Stock

6.68 USD

+0.23 (+3.57%)

Last: 11/19/2025, 2:57:57 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KLRS Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Benzinga - Mentions: DERM INTS LPTX CMND ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

8 days ago - By: Kalaris Therapeutics, Inc.

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

17 days ago - By: Kalaris Therapeutics, Inc.

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

a month ago - By: Benzinga - Mentions: ONMD RLMD AQB LPTX ...

12 Health Care Stocks Moving In Monday's Intraday Session

3 months ago - By: The Motley Fool

Kalaris Reports Loss Cash at 88 Million

2 months ago - By: Kalaris Therapeutics, Inc.

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

3 months ago - By: Zacks Investment Research

Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know

3 months ago - By: Kalaris Therapeutics, Inc.

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

6 months ago - By: Kalaris Therapeutics, Inc.

Kalaris to Participate at Stifel Ophthalmology Forum

6 months ago - By: Kalaris Therapeutics, Inc.

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

8 months ago - By: Kalaris Therapeutics, Inc.

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

8 months ago - By: Kalaris Therapeutics, Inc.

Kalaris Announces Closing of Merger with AlloVir